Skip to main content
Home / Allergy and Asthma Proceedings, Volume 28, Supplement 1

Optimization of intranasal corticosteroid formulations for the treatment of allergic rhinitis

Buy Article:

$36.50 + tax (Refund Policy)

Authors: Wingertzahn, Mark A. 1 ; Derebery, M. Jennifer 2 ; Nelson, Harold S. 3 ; 

Source: Allergy and Asthma Proceedings, Volume 28, Supplement 1, May-June 2007, pp. s18-s24(7)

Publisher: OceanSide Publications, Inc

DOI: https://doi.org/10.2500/aap.2007.28.2993

Intranasal corticosteroids (INCSs) provide safe and effective treatment of allergic rhinitis (AR). Currently available INCSs differ in terms of the components included in each formulation that may influence efficacy, tolerability, and patient preference for treatment. Patient preference for a specific INCS is largely attributable to the sensory attributes that are dependent on characteristics of the formulation. Preservatives and additives can irritate and dry the mucosal membranes, or they can confer an unpleasant odor or taste to an INCS formulation. Spray volume also may affect patients' sensory perceptions of INCS formulations. Relative osmotic pressure or tonicity may affect nasal absorption and retention of an INCS and potentially affect clinical efficacy. A hypotonic suspension is a new formulation option for INCSs that may improve sensory attributes and has the potential to improve patient satisfaction and treatment outcomes in patients with AR. Optimization of INCS formulations may improve efficacy and tolerability and influence patient preference for treatment.

Keywords: Allergic rhinitis; benzalkonium chloride; ciclesonide; efficacy; intranasal corticosteroids; patient preference; preservatives; rhinitis; tolerability; tonicity

Document Type: Research Article

Affiliations: 1: ALTANA Pharma US, Florham Park, New Jersey 2: House Ear Clinic, Los Angeles, California 3: National Jewish Medical and Research Center, Denver, Colorado

Publication date: 01 May 2007

More about this publication?
  • Allergy and Asthma Proceedings is a peer reviewed publication dedicated to distributing timely scientific research regarding advancements in the knowledge and practice of allergy, asthma and immunology. Its primary readership consists of allergists and pulmonologists.

    The goal of the Proceedings is to publish articles with a predominantly clinical focus which directly impact quality of care for patients with allergic disease and asthma and by having the potential to directly impact the quality of patient care. AAP welcomes the submission of original works including peer-reviewed original research and clinical trial results. Additionally, as the official journal of the Eastern Allergy Conference (EAC), AAP will publish content from EAC poster sessions as well as review articles derived from EAC lectures.

    Featured topics include asthma, rhinitis, sinusitis, food allergies, allergic skin diseases, diagnostic techniques, allergens, and treatment modalities. Published material includes peer-reviewed original research, clinical trials and review articles.

    Articles marked "F" offer free full text for personal noncommercial use only.

    The journal is indexed in Thomson Reuters Web of Science and Science Citation Index Expanded, plus the National Library of Medicine's PubMed service.
  • Editorial Board
  • Information for Authors
  • Submit a Paper
  • Information for Advertisers
  • Reprint Requests
  • Commercial level: Permission to use content
  • www.JFoodAllergy.com
  • Ingenta Connect is not responsible for the content or availability of external websites

Share Content

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content